Aug 2026· Pharmaceuticals· Vol 19, pp. 1270· 0 citations· 36 references
Medicine
TL;DR
Compound 7 represents a selective, mid-micromolar benzimidazole-hydrazone lead against MCF-7 breast cancer cells, and its predicted molecular interactions warrant further target-based, mechanistic, pharmacokinetic, and in vivo evaluation.
Abstract
Background/Objectives: Benzimidazole and hydrazone scaffolds are widely investigated in anticancer drug discovery because of their structural versatility and capacity to interact with multiple cancer-related targets. This study aimed to synthesize a series of trifluoromethyl-substituted benzimidazole-hydrazone derivatives, evaluate their antiproliferative activity and cancer-cell selectivity, and explore their potential interactions with breast cancer-associated molecular targets. Methods: A series of benzimidazole-hydrazone derivatives were prepared through a four-step synthetic route using both conventional and microwave-assisted procedures. The structures of the synthesized compounds were characterized using spectroscopic and analytical methods. Antiproliferative activity was evaluated in estrogen receptor-positive MCF-7 human breast cancer cells using the MTT assay after 48 h of exposure. Selected active compounds were additionally tested against non-tumorigenic hTERT cells to determine their selectivity indices. In silico analyses were performed against estrogen receptor alpha in antagonist and selective estrogen receptor degrader conformations, bromodomain-containing protein 4, and the mTOR kinase domain. Results: Microwave irradiation substantially reduced reaction times from 12–24 h to 4–6 min and increased isolated yields by 7–24 percentage points compared with conventional conditions. Compounds 4, 7, 9, and 11 reduced MCF-7 cell viability below 50% at 20 μM. Compound 7 showed the highest antiproliferative activity, with an IC50 value of 7.5 ± 0.8 μM, and the greatest selectivity toward MCF-7 cells over hTERT cells, with a selectivity index of 12.66. Molecular docking, MD simulation, and MM/GBSA calculations predicted that compound 7 would effectively bind to the investigated targets, particularly estrogen receptor alpha, as well as the BRD4 and mTOR kinase domains. Conclusions: Compound 7 represents a selective, mid-micromolar benzimidazole-hydrazone lead against MCF-7 breast cancer cells. Its predicted molecular interactions warrant further target-based, mechanistic, pharmacokinetic, and in vivo evaluation.
Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways.
Guzide Satir-Basaran, Ahmed Amleh, Antonio Curcio et al.· Bioorganic chemistry (Print)· 0 citations
A series of diphenylpropan-1-one (DPP) derivatives (4a–4i), rationally designed around a chalcone framework and synthesized via a three-step reaction sequence demonstrated encouraging preliminary anticancer potential and may serve as promising lead molecules for future investigations.
A. Najmi, M. S. Alam, W. Ahsan et al.· RSC Advances· 0 citations
The synthesized benzoxazole hybrid compounds showed promising anticancer activity with acceptable ADMET properties; however, further structural optimization and mechanistic studies are needed to validate the molecular targets and improve safety and pharmacokinetic profiles.
Mahmoud A. Al-Sha'er, A. H. Abdullah, Almeqdad Y. Habashneh et al.· Chemistry Africa· 0 citations
The findings suggest adamantane as a feasible backbone to develop anticancer agents which may act in-part via CDC25A interaction, suggest adamantane as a feasible backbone to develop anticancer agents which may act in-part via CDC25A.
M. Alamri, Yassine Riadi, M. Alamri et al.· Computational biology and ch...· 0 citations
Promising compounds like SBB-2, SBB-3, SBB-5, SBB-6, and SBB-7 exhibit favourable physicochemical properties, high drug-likeness, solubility, and a non-toxic profile, making them strong candidates for further development of a promising drug.
D. Upadhyay, Drashti Thanki, C. Somaiya· Current Organic Synthesis· 0 citations
Overall, the moderate promising leads of NT1 and NT9 emerged with dual-target potential for breast cancer, supporting further optimization and preclinical assessment.
C. N. Babu, Mazin Aboobaida Abdalla Abdelaziz, N. Nizamuddin et al.· Journal of Pharmaceutical In...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.